Protocol Components
- 1 panel Total testosterone, free testosterone, SHBG (morning fasted draw)
- 1 panel Estradiol (sensitive assay), LH, FSH, prolactin
- 1 panel CBC, CMP, lipids, PSA, thyroid panel
- 1 panel hsCRP, fasting insulin, HbA1c, ApoB
- 1 panel Vitamin D (25-OH), ferritin, iron panel
- 100–160mg/wk Testosterone cypionate or enanthate (split into 2x weekly injections)
- 500–1000 IU hCG, 2–3x weekly (testicular preservation)
- 0.25mg Anastrozole, as needed (only if estradiol exceeds 50 pg/mL with symptoms)
- 5,000 IU Vitamin D3 daily (target 50–70 ng/mL)
- 200mg Magnesium glycinate nightly
- 3g Omega-3 (EPA/DHA) daily (target Omega-3 Index ≥8%)
- 5g Creatine monohydrate daily
- 200mcg Vitamin K2 (MK-7) daily
- Week 6 Follow-up labs: total/free T, estradiol, hematocrit, lipids
- Week 12 Full panel repeat + DEXA scan (body composition baseline)
- Every 6 mo Comprehensive labs, coronary calcium score annually
Step-by-Step Protocol
Establish your baseline. Run the full lab panel above before touching testosterone. You need to know your starting hematocrit, estradiol, lipids, and inflammatory markers. Most longevity-focused TRT failures come from skipping this step — you can't optimize what you haven't measured.
Start conservatively. Begin at 100–120mg/week split into two injections (e.g., Monday/Thursday). This mimics physiological rhythm better than once-weekly dosing and reduces estradiol spikes. Use a 27–29 gauge insulin needle — subcutaneous or shallow IM in the deltoid or ventrogluteal site.
Add hCG from day one. 500–1000 IU, 2–3x per week. This preserves testicular function, intratesticular testosterone production, and fertility. For men under 50 who may want future children, hCG is non-negotiable. It also supports pregnenolone and progesterone pathways that pure TRT can suppress.
Layer in the longevity support. Vitamin D, magnesium, omega-3s, creatine, and K2 aren't optional add-ons — they're the foundation that makes TRT work synergistically with longevity goals. Creatine alone has emerging evidence for brain protection, bone density, and mitochondrial function beyond its muscle benefits.
Tune at week 6. Repeat labs. If total testosterone is in the 600–900 ng/dL range with free T mid-upper reference, hematocrit below 52%, and estradiol under 50 pg/mL without symptoms — you're in the sweet spot. Adjust dose by 10–20mg increments, not leaps. If estradiol is elevated, consider dose reduction before adding anastrozole.
Evaluate at week 12. Full lab panel plus DEXA body composition. Compare to baseline. Look for improvements in: lean mass, visceral fat, fasting insulin, hsCRP, and subjective markers (energy, libido, mood, recovery). If hematocrit exceeds 54%, donate blood and reduce dose by 20mg. This is a marathon, not a sprint.
Protocol Tips
- Twice-weekly injections cut estradiol spikes by ~30% compared to once-weekly. Smaller, more frequent doses = more stable levels = fewer side effects.
- Never start anastrozole prophylactically. Estradiol is cardioprotective and neuroprotective. Only suppress it if it's genuinely elevated AND causing symptoms (bloating, mood, gynecomastia).
- Track your ApoB, not just LDL. TRT can shift lipid profiles. ApoB is the particle count that actually predicts cardiovascular risk — target under 90 mg/dL for longevity.
- Hydrate aggressively. Testosterone increases red blood cell production. Hematocrit climbs faster when you're dehydrated. Aim for 3–4 liters daily minimum.
- Re-evaluate annually. TRT isn't "set and forget." Your body, goals, and risk profile change. The protocol that's right at 40 may need adjustment at 50.
Protocol Variations
The Minimalist (Under 40, No Symptoms)
Start with lifestyle optimization only — Zone 2 cardio 3x/week, resistance training 3x/week, sleep optimization, vitamin D + zinc + magnesium. Recheck labs in 90 days. Many men under 40 can restore testosterone to 500+ ng/dL without exogenous hormones. TRT is the last resort, not the first move.
The Cardiovascular-First Protocol
For men with elevated ApoB, family history of heart disease, or coronary calcium score >0. Add ezetimibe 10mg and/or low-dose rosuvastatin alongside TRT. Monitor lipids every 3 months. The longevity benefit of optimized testosterone is meaningless if you're accelerating atherosclerosis. Manage the risk aggressively.
The Cognitive Focus Stack
For men prioritizing brain health. Add: lion's mane 1g daily, creatine 5g daily (brain ATP support), alpha-GPC 300mg daily. Keep testosterone at mid-range (500–700 ng/dL) rather than pushing high — emerging data suggests supraphysiological levels may not benefit cognition and could increase risk.
The Athletic Longevity Protocol
For men training for the centenarian decathlon. Higher end of dosing (140–160mg/wk) with emphasis on maintaining lean mass and VO2 max. Add Zone 2 cardio 4x/week, VO2 max intervals 1x/week, and eccentric strength training. Monitor joint health, tendon integrity, and recovery metrics. The goal is functional capacity at 80, not peak performance at 45.
The Enclomiphene Alternative
For men who want to raise testosterone without shutting down the HPTA axis. Enclomiphene citrate 12.5–25mg daily stimulates LH/FSH, raising endogenous testosterone. Less data than TRT, but preserves fertility naturally and avoids testicular atrophy. Best for men in their 30s–40s with secondary hypogonadism (low LH-driven). Evidence tier: promising.
Why This Formula Works
Promising The testosterone-longevity relationship is nuanced. Observational data from the Journal of the American College of Cardiology (2024) shows men with total testosterone in the 450–600 ng/dL range have the lowest all-cause mortality. Below 300 ng/dL, cardiovascular risk and metabolic syndrome rates climb sharply. Above 900 ng/dL, the data is less clear — some studies show diminishing returns or increased hematocrit-related risks.
Established What IS well-established: low testosterone independently predicts insulin resistance, visceral fat accumulation, sarcopenia, cognitive decline, and depression — all of which accelerate biological aging. The T Trials (2016) demonstrated that raising testosterone in hypogonadal men improved bone density, mood, and sexual function with no increased cardiovascular events over 12 months. The TRAVERSE trial (2023) — the largest RCT to date — confirmed cardiovascular safety at therapeutic doses.
The longevity framework here isn't "more testosterone = longer life." It's: normalize testosterone to physiological range, protect the HPTA axis, manage downstream risks (hematocrit, estradiol, lipids), and layer in evidence-based support compounds. Think of TRT as one ingredient in a broader longevity stack — not the whole recipe.